The 2026 Trial Landscape in the United States
This year's American Diabetes Association Scientific Sessions in New Orleans put the pace of change on full display. Researchers shared findings from the ACHIEVE program, which studied orforglipron, the first oral small-molecule GLP-1 receptor agonist to complete a phase 3 program. For people who have avoided injectable therapies, an effective pill could reshape their daily routine. A separate phase 2 study from Novo Nordisk showed that zenagamtide, a single molecule that activates both GLP-1 and amylin receptors, lowered HbA1c by up to 1.56 percentage points more than placebo at the highest dose over 36 weeks. Most participants in that dose group reached a target below 6.5 percent, and weight loss followed a similar pattern.
The momentum is not limited to type 2 diabetes. Eli Lilly is studying combinations of macupatide and eloralintide in adults with obesity and type 2 diabetes, while Roche is enrolling a large phase 3 trial of enicepatide, a dual GLP-1 and GIP receptor agonist. For people with type 1 diabetes, a first study of the twiist automated insulin delivery system followed 20 adults over eight weeks and measured time in range between 70 and 180 mg/dL. Across the country, searches for diabetes clinical trials near me keep climbing, which suggests a growing appetite for options that feel real and reachable.
Why Many Eligible Adults Hold Back
The gap between interest and enrollment is wide, and the reasons are understandable.
- Eligibility confusion. Criteria like HbA1c range, BMI, and current medication lists read like a foreign language to most people.
- Fear of randomization. The thought of receiving a placebo instead of an active drug stops many before they even ask.
- Logistics. Travel, time off work, and uncertainty about costs feel like steep barriers.
- The after-story. People worry about what happens to their care once the study wraps up.
None of these concerns are unreasonable. The fix is information, and the trial teams know it. Most coordinators are happy to walk you through every detail before you sign anything.
What a Trial Actually Looks Like
Here is what a typical diabetes research study involves: a screening visit to confirm eligibility, an informed consent conversation, then regular check-ins where a coordinator tracks glucose, weight, and any side effects. Many programs provide a continuous glucose monitor and a study app so you can see your numbers between visits. Investigational treatment and monitoring devices are supplied by the study sponsor during the trial, and compensation is common for your time and travel.
Take Karen, a 58-year-old teacher from Tempe, Arizona. She had been on metformin for years and watched her HbA1c creep upward. Her endocrinologist mentioned a nearby obesity and diabetes study, and after one phone call with the coordinator, she understood the commitment, the visit schedule, and the compensation. The closer monitoring alone gave her a level of confidence she had not felt in a decade. Her experience is typical of people who treat a trial like a team project rather than a gamble.
Comparing the Main Types of Trials
| Trial Type | Recent Example | Typical Length | Best Fit | Key Considerations |
|---|
| Oral GLP-1 drug studies | ACHIEVE program (orforglipron) | Around 36 weeks | Adults with type 2 diabetes who prefer pills | Daily dosing, regular blood draws, glucose logs |
| Dual agonist metabolic trials | Zenagamtide (Novo Nordisk) | 36 weeks | Adults with type 2 diabetes and overweight | Injection, possible mild GI side effects, weight tracking |
| Combination therapy studies | Macupatide and eloralintide (Eli Lilly) | About 48 weeks | Adults with obesity and type 2 diabetes | Multiple injections, longer commitment |
| Automated insulin delivery | twiist AID system | 8 weeks | Adults with type 1 diabetes on insulin | Wearable device, frequent CGM review |
| Diet and digital programs | VITAL-CGM at Stanford | 12 months | Adults aged 18 to 69 with type 2 diabetes | Remote sessions, app-based tracking, per-visit compensation |
Each category answers a different question. Drug trials ask whether a new molecule works better than current options. Device studies test whether new technology is safe and usable in daily life. Lifestyle programs ask whether digital coaching can move the numbers that matter. Matching your own priorities to the right category makes the whole experience less intimidating.
How to Find and Join a Study Near You
Start with your own care team. Your endocrinologist or primary care doctor knows your history and can flag studies that fit your profile. Then use ClinicalTrials.gov with your ZIP code and filter by recruiting status and diabetes type. This is the single most useful tool for finding affordable diabetes clinical trials in your region, since you can see locations, phase, and enrollment details at a glance.
When you contact a coordinator, come prepared with five questions. What are the odds of receiving placebo? How many visits and where? What compensation and travel support is offered? What happens when the study ends, including access to the treatment afterward? And who covers medical care for any issue that comes up during the study? Good coordinators answer all of these without hesitation.
Many studies recruit across multiple states. Novo Nordisk runs sites in Phoenix, Arizona, and Lincoln, Nebraska. Stanford's Diabetes Research Center lists digital weight management and meal timing studies with sessions that can be done remotely. If you live in a smaller town, ask whether the study offers satellite visits or virtual check-ins. More programs than ever allow you to see the research team less often and still stay connected.
A Note on Cost Support
Cost is a fair concern, so let's talk numbers honestly. Compensation varies by study and commitment. Stanford's VITAL-CGM program pays roughly $50 to $75 per visit, while a longer type 1 diabetes diet study in Boston offered up to $1,300 for full participation. Many trials also reimburse parking and mileage. During the study, the investigational treatment and devices are provided by the sponsor, which can remove a meaningful monthly expense from your budget. Ask directly about cost support options, because these details are rarely advertised on a listing page.
What to Ask Before You Say Yes
Two more points deserve attention before you sign. First, understand the timeline not just for visits but for results. A phase 2 study might last months, while a phase 3 program can stretch well beyond a year. Make sure the schedule fits your life, not the other way around. Second, talk to a family member or friend about your decision. Diabetes care is a daily team effort, and having someone who knows what you signed up for makes adherence easier.
The registry itself is your safety net. Every study on ClinicalTrials.gov lists a contact person, and that person's job is to answer questions without pressure. If anything feels rushed or unclear, walk away. There will be another study.
One Last Note for the Road
Trials are not a side door to healthcare. They are a legitimate, well-monitored path to treatments that may not reach your pharmacy for years. The people running them want engaged participants, and the compensation and monitoring reflect that. Whether you live in Austin, Chicago, or a town of five thousand, a conversation with your doctor about clinical trial participation costs nothing and could change how you manage your numbers.
Browse the registry this week with your ZIP code in hand. Call one coordinator. Ask your five questions. That single step is how most of the people enrolled in these studies got started, and it is exactly where you should begin.
研究の知恵